Nano Biotechnology

Nano Biotechnology Comprehensive Study by Application (Drug Delivery Systems, Diagnostics and Imaging, Others), Therapeutics (Cancer, Dental, Cardiac, Orthopaedic, Others), End User (Pharmaceuticals, Medical Devices, Medical Research, Food and Agriculture, Others) Players and Region - Global Market Outlook to 2032

Nano Biotechnology Market by XX Submarkets | Forecast Years 2025-2032  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Nano Biotechnology
Nanobiotechnology is the combination of nanotechnology and the biotechnology field and the study of biological systems at the nanoscale level, typically involving molecules and small particles. Nanobiology and bio nanotechnology are other names that are used interchangeably with nanobiotechnology. It involves the application of nanomaterials, nanodevices, and nanoscale techniques to understand, interact with, and control biological processes, leading to a wide range of practical applications across various industries. These sectors are medicine & healthcare, biomedical research institutes, agriculture & food industry, energy & environment companies, IT and others. The increasing use and application of Nanobiotechnology is a key driver for Nanobiotechnology Market growth. North Carolina is a global leader in nanobiotechnology, with universities and industry focused on nanoscience research and applications. Nanobiotechnology is gathering substantial investment from businesses and governments globally. In the healthcare sector, nanobiotechnology is transforming the way diseases are diagnosed and treated. For instance, nanoparticles are being used to deliver drugs directly to cancer cells, thereby minimizing the side effects associated with traditional chemotherapy. This targeted approach to treatment is not only improving patient outcomes but also opening up new markets for pharmaceutical companies. Also, nanobiotechnology is enabling the development of rapid diagnostic tools that detect diseases at their earliest stages, thus facilitating timely intervention and reducing healthcare costs.

AttributesDetails
Study Period2020-2032
Base Year2024
UnitValue (USD Million)


The Nanobiotechnology Market involved various companies, research institutions, and universities. Leading players focus on extensive research and development to drive innovation in nanomedicines, nanosensors, and therapeutic applications. They actively engage in strategic partnerships and collaborations with academic institutions and healthcare providers to accelerate product development and commercialization. Market expansion efforts involve establishing a global presence, targeting emerging economies, and obtaining regulatory approvals. Key developments include frequent product launches, mergers, acquisitions, securing funding, and protecting intellectual property. The competitive landscape is characterized by a dynamic interplay of innovation, strategic alliances, and efforts to capitalize on diverse applications across healthcare, agriculture, energy, and the environment. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Nano Biotechnology market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Nami Therapeutics (United States), Celgene Corporation (United States), Nanophase Technologies Corporation (United States), Sigma-Aldrich (United States), Ablynx (Belgium), SkyePharma Pharmaceuticals (France), Nano Bridging Molecules SA (Switzerland), XanTecbioanalytics GmbH (Germany), Nanobiotix(France) and Indian Institute of Science (IISc) (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are National University of Singapore (NUS) (Singapore), Chinese Academy of Sciences (CAS) (China), National Institute of Advanced Industrial Science and Technology (AIST) (Japan), Johnson & Johnson (United States), Abbott Laboratories (United States) and Novartis AG (United States).

Segmentation Overview
AMA Research has segmented the market of Global Nano Biotechnology market by , Application (Drug Delivery Systems, Diagnostics and Imaging and Others) and Region.



On the basis of geography, the market of Nano Biotechnology has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Therapeutics, the sub-segment i.e. Cancer will boost the Nano Biotechnology market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Pharmaceuticals will boost the Nano Biotechnology market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Demand for Personalized Medicine

Market Growth Drivers:
Rising Prevalence of Chronic Diseases and Growth in Nanomedicine & Tissue Engineering

Challenges:
Toxicity & Safety Concerns

Restraints:
High Development Costs

Opportunities:
Advancements in Drug Delivery Systems and Technological Innovations in Diagnostics

Market Leaders and their expansionary development strategies
In January 2025, the Nano and Advanced Materials Institute (NAMI) announced plans to unveil its smart products and new collaborations at CES 2025. This move underscores the growing interest in integrating nanobiotechnology into consumer products and the importance of partnerships in driving innovation.
In December 2024, the National Nanotechnology Coordination Office released the NNI Supplement to the President's 2025 Budget, highlighting a continued emphasis on fundamental research in nanoscience and programs to advance applications, devices, and systems.


Key Target Audience
Manufactures Companies, Research and Development Institutions, Raw Material Suppliers and Distributors and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Drug Delivery Systems
  • Diagnostics and Imaging
  • Others
By Therapeutics
  • Cancer
  • Dental
  • Cardiac
  • Orthopaedic
  • Others

By End User
  • Pharmaceuticals
  • Medical Devices
  • Medical Research
  • Food and Agriculture
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Chronic Diseases
      • 3.2.2. Growth in Nanomedicine & Tissue Engineering
    • 3.3. Market Challenges
      • 3.3.1. Toxicity & Safety Concerns
    • 3.4. Market Trends
      • 3.4.1. Growing Demand for Personalized Medicine
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Nano Biotechnology, by Application, Therapeutics, End User and Region (value) (2019-2024)
    • 5.1. Introduction
    • 5.2. Global Nano Biotechnology (Value)
      • 5.2.1. Global Nano Biotechnology by: Application (Value)
        • 5.2.1.1. Drug Delivery Systems
        • 5.2.1.2. Diagnostics and Imaging
        • 5.2.1.3. Others
      • 5.2.2. Global Nano Biotechnology by: Therapeutics (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Dental
        • 5.2.2.3. Cardiac
        • 5.2.2.4. Orthopaedic
        • 5.2.2.5. Others
      • 5.2.3. Global Nano Biotechnology by: End User (Value)
        • 5.2.3.1. Pharmaceuticals
        • 5.2.3.2. Medical Devices
        • 5.2.3.3. Medical Research
        • 5.2.3.4. Food and Agriculture
        • 5.2.3.5. Others
      • 5.2.4. Global Nano Biotechnology Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Nano Biotechnology: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2024)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Nami Therapeutics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Celgene Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Nanophase Technologies Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sigma-Aldrich (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Ablynx (Belgium)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. SkyePharma Pharmaceuticals (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Nano Bridging Molecules SA (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. XanTecbioanalytics GmbH (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Nanobiotix(France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Indian Institute of Science (IISc) (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Nano Biotechnology Sale, by Application, Therapeutics, End User and Region (value) (2027-2032)
    • 7.1. Introduction
    • 7.2. Global Nano Biotechnology (Value)
      • 7.2.1. Global Nano Biotechnology by: Application (Value)
        • 7.2.1.1. Drug Delivery Systems
        • 7.2.1.2. Diagnostics and Imaging
        • 7.2.1.3. Others
      • 7.2.2. Global Nano Biotechnology by: Therapeutics (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Dental
        • 7.2.2.3. Cardiac
        • 7.2.2.4. Orthopaedic
        • 7.2.2.5. Others
      • 7.2.3. Global Nano Biotechnology by: End User (Value)
        • 7.2.3.1. Pharmaceuticals
        • 7.2.3.2. Medical Devices
        • 7.2.3.3. Medical Research
        • 7.2.3.4. Food and Agriculture
        • 7.2.3.5. Others
      • 7.2.4. Global Nano Biotechnology Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Nano Biotechnology: by Application(USD Million)
  • Table 2. Nano Biotechnology Drug Delivery Systems , by Region USD Million (2019-2024)
  • Table 3. Nano Biotechnology Diagnostics and Imaging , by Region USD Million (2019-2024)
  • Table 4. Nano Biotechnology Others , by Region USD Million (2019-2024)
  • Table 5. Nano Biotechnology: by Therapeutics(USD Million)
  • Table 6. Nano Biotechnology Cancer , by Region USD Million (2019-2024)
  • Table 7. Nano Biotechnology Dental , by Region USD Million (2019-2024)
  • Table 8. Nano Biotechnology Cardiac , by Region USD Million (2019-2024)
  • Table 9. Nano Biotechnology Orthopaedic , by Region USD Million (2019-2024)
  • Table 10. Nano Biotechnology Others , by Region USD Million (2019-2024)
  • Table 11. Nano Biotechnology: by End User(USD Million)
  • Table 12. Nano Biotechnology Pharmaceuticals , by Region USD Million (2019-2024)
  • Table 13. Nano Biotechnology Medical Devices , by Region USD Million (2019-2024)
  • Table 14. Nano Biotechnology Medical Research , by Region USD Million (2019-2024)
  • Table 15. Nano Biotechnology Food and Agriculture , by Region USD Million (2019-2024)
  • Table 16. Nano Biotechnology Others , by Region USD Million (2019-2024)
  • Table 17. South America Nano Biotechnology, by Country USD Million (2019-2024)
  • Table 18. South America Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 19. South America Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 20. South America Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 21. Brazil Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 22. Brazil Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 23. Brazil Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 24. Argentina Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 25. Argentina Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 26. Argentina Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 27. Rest of South America Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 28. Rest of South America Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 29. Rest of South America Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 30. Asia Pacific Nano Biotechnology, by Country USD Million (2019-2024)
  • Table 31. Asia Pacific Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 32. Asia Pacific Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 33. Asia Pacific Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 34. China Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 35. China Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 36. China Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 37. Japan Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 38. Japan Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 39. Japan Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 40. India Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 41. India Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 42. India Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 43. South Korea Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 44. South Korea Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 45. South Korea Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 46. Taiwan Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 47. Taiwan Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 48. Taiwan Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 49. Australia Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 50. Australia Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 51. Australia Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 52. Rest of Asia-Pacific Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 53. Rest of Asia-Pacific Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 54. Rest of Asia-Pacific Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 55. Europe Nano Biotechnology, by Country USD Million (2019-2024)
  • Table 56. Europe Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 57. Europe Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 58. Europe Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 59. Germany Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 60. Germany Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 61. Germany Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 62. France Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 63. France Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 64. France Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 65. Italy Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 66. Italy Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 67. Italy Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 68. United Kingdom Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 69. United Kingdom Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 70. United Kingdom Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 71. Netherlands Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 72. Netherlands Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 73. Netherlands Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 74. Rest of Europe Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 75. Rest of Europe Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 76. Rest of Europe Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 77. MEA Nano Biotechnology, by Country USD Million (2019-2024)
  • Table 78. MEA Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 79. MEA Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 80. MEA Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 81. Middle East Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 82. Middle East Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 83. Middle East Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 84. Africa Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 85. Africa Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 86. Africa Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 87. North America Nano Biotechnology, by Country USD Million (2019-2024)
  • Table 88. North America Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 89. North America Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 90. North America Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 91. United States Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 92. United States Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 93. United States Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 94. Canada Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 95. Canada Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 96. Canada Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 97. Mexico Nano Biotechnology, by Application USD Million (2019-2024)
  • Table 98. Mexico Nano Biotechnology, by Therapeutics USD Million (2019-2024)
  • Table 99. Mexico Nano Biotechnology, by End User USD Million (2019-2024)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Nano Biotechnology: by Application(USD Million)
  • Table 111. Nano Biotechnology Drug Delivery Systems , by Region USD Million (2027-2032)
  • Table 112. Nano Biotechnology Diagnostics and Imaging , by Region USD Million (2027-2032)
  • Table 113. Nano Biotechnology Others , by Region USD Million (2027-2032)
  • Table 114. Nano Biotechnology: by Therapeutics(USD Million)
  • Table 115. Nano Biotechnology Cancer , by Region USD Million (2027-2032)
  • Table 116. Nano Biotechnology Dental , by Region USD Million (2027-2032)
  • Table 117. Nano Biotechnology Cardiac , by Region USD Million (2027-2032)
  • Table 118. Nano Biotechnology Orthopaedic , by Region USD Million (2027-2032)
  • Table 119. Nano Biotechnology Others , by Region USD Million (2027-2032)
  • Table 120. Nano Biotechnology: by End User(USD Million)
  • Table 121. Nano Biotechnology Pharmaceuticals , by Region USD Million (2027-2032)
  • Table 122. Nano Biotechnology Medical Devices , by Region USD Million (2027-2032)
  • Table 123. Nano Biotechnology Medical Research , by Region USD Million (2027-2032)
  • Table 124. Nano Biotechnology Food and Agriculture , by Region USD Million (2027-2032)
  • Table 125. Nano Biotechnology Others , by Region USD Million (2027-2032)
  • Table 126. South America Nano Biotechnology, by Country USD Million (2027-2032)
  • Table 127. South America Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 128. South America Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 129. South America Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 130. Brazil Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 131. Brazil Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 132. Brazil Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 133. Argentina Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 134. Argentina Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 135. Argentina Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 136. Rest of South America Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 137. Rest of South America Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 138. Rest of South America Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 139. Asia Pacific Nano Biotechnology, by Country USD Million (2027-2032)
  • Table 140. Asia Pacific Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 141. Asia Pacific Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 142. Asia Pacific Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 143. China Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 144. China Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 145. China Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 146. Japan Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 147. Japan Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 148. Japan Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 149. India Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 150. India Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 151. India Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 152. South Korea Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 153. South Korea Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 154. South Korea Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 155. Taiwan Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 156. Taiwan Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 157. Taiwan Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 158. Australia Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 159. Australia Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 160. Australia Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 161. Rest of Asia-Pacific Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 162. Rest of Asia-Pacific Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 163. Rest of Asia-Pacific Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 164. Europe Nano Biotechnology, by Country USD Million (2027-2032)
  • Table 165. Europe Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 166. Europe Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 167. Europe Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 168. Germany Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 169. Germany Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 170. Germany Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 171. France Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 172. France Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 173. France Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 174. Italy Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 175. Italy Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 176. Italy Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 177. United Kingdom Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 178. United Kingdom Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 179. United Kingdom Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 180. Netherlands Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 181. Netherlands Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 182. Netherlands Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 183. Rest of Europe Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 184. Rest of Europe Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 185. Rest of Europe Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 186. MEA Nano Biotechnology, by Country USD Million (2027-2032)
  • Table 187. MEA Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 188. MEA Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 189. MEA Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 190. Middle East Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 191. Middle East Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 192. Middle East Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 193. Africa Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 194. Africa Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 195. Africa Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 196. North America Nano Biotechnology, by Country USD Million (2027-2032)
  • Table 197. North America Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 198. North America Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 199. North America Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 200. United States Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 201. United States Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 202. United States Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 203. Canada Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 204. Canada Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 205. Canada Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 206. Mexico Nano Biotechnology, by Application USD Million (2027-2032)
  • Table 207. Mexico Nano Biotechnology, by Therapeutics USD Million (2027-2032)
  • Table 208. Mexico Nano Biotechnology, by End User USD Million (2027-2032)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nano Biotechnology: by Application USD Million (2019-2024)
  • Figure 5. Global Nano Biotechnology: by Therapeutics USD Million (2019-2024)
  • Figure 6. Global Nano Biotechnology: by End User USD Million (2019-2024)
  • Figure 7. South America Nano Biotechnology Share (%), by Country
  • Figure 8. Asia Pacific Nano Biotechnology Share (%), by Country
  • Figure 9. Europe Nano Biotechnology Share (%), by Country
  • Figure 10. MEA Nano Biotechnology Share (%), by Country
  • Figure 11. North America Nano Biotechnology Share (%), by Country
  • Figure 12. Global Nano Biotechnology share by Players 2024 (%)
  • Figure 13. Global Nano Biotechnology share by Players (Top 3) 2024(%)
  • Figure 14. Global Nano Biotechnology share by Players (Top 5) 2024(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Nami Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 17. Nami Therapeutics (United States) Revenue: by Geography 2024
  • Figure 18. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 19. Celgene Corporation (United States) Revenue: by Geography 2024
  • Figure 20. Nanophase Technologies Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 21. Nanophase Technologies Corporation (United States) Revenue: by Geography 2024
  • Figure 22. Sigma-Aldrich (United States) Revenue, Net Income and Gross profit
  • Figure 23. Sigma-Aldrich (United States) Revenue: by Geography 2024
  • Figure 24. Ablynx (Belgium) Revenue, Net Income and Gross profit
  • Figure 25. Ablynx (Belgium) Revenue: by Geography 2024
  • Figure 26. SkyePharma Pharmaceuticals (France) Revenue, Net Income and Gross profit
  • Figure 27. SkyePharma Pharmaceuticals (France) Revenue: by Geography 2024
  • Figure 28. Nano Bridging Molecules SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Nano Bridging Molecules SA (Switzerland) Revenue: by Geography 2024
  • Figure 30. XanTecbioanalytics GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 31. XanTecbioanalytics GmbH (Germany) Revenue: by Geography 2024
  • Figure 32. Nanobiotix(France) Revenue, Net Income and Gross profit
  • Figure 33. Nanobiotix(France) Revenue: by Geography 2024
  • Figure 34. Indian Institute of Science (IISc) (India) Revenue, Net Income and Gross profit
  • Figure 35. Indian Institute of Science (IISc) (India) Revenue: by Geography 2024
  • Figure 36. Global Nano Biotechnology: by Application USD Million (2027-2032)
  • Figure 37. Global Nano Biotechnology: by Therapeutics USD Million (2027-2032)
  • Figure 38. Global Nano Biotechnology: by End User USD Million (2027-2032)
  • Figure 39. South America Nano Biotechnology Share (%), by Country
  • Figure 40. Asia Pacific Nano Biotechnology Share (%), by Country
  • Figure 41. Europe Nano Biotechnology Share (%), by Country
  • Figure 42. MEA Nano Biotechnology Share (%), by Country
  • Figure 43. North America Nano Biotechnology Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Nami Therapeutics (United States)
  • Celgene Corporation (United States)
  • Nanophase Technologies Corporation (United States)
  • Sigma-Aldrich (United States)
  • Ablynx (Belgium)
  • SkyePharma Pharmaceuticals (France)
  • Nano Bridging Molecules SA (Switzerland)
  • XanTecbioanalytics GmbH (Germany)
  • Nanobiotix(France)
  • Indian Institute of Science (IISc) (India)
Additional players considered in the study are as follows:
National University of Singapore (NUS) (Singapore) , Chinese Academy of Sciences (CAS) (China) , National Institute of Advanced Industrial Science and Technology (AIST) (Japan) , Johnson & Johnson (United States) , Abbott Laboratories (United States) , Novartis AG (United States)
Select User Access Type

Key Highlights of Report


Feb 2025 212 Pages 95 Tables Base Year: 2024 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Nano Biotechnology Quantitative research analysis
Nano Biotechnology Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Nami Therapeutics (United States), Celgene Corporation (United States), Nanophase Technologies Corporation (United States), Sigma-Aldrich (United States), Ablynx (Belgium), SkyePharma Pharmaceuticals (France), Nano Bridging Molecules SA (Switzerland), XanTecbioanalytics GmbH (Germany), Nanobiotix(France) and Indian Institute of Science (IISc) (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Demand for Personalized Medicine" is seen as one of major influencing trends for Nano Biotechnology Market during projected period 2024-2032.
The Nano Biotechnology market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Nano Biotechnology Report?

Have a Query? Click Here

Other Related Reports

CBCT System Comprehensive Study by Type (Image Intensifier Detector, Flat-Panel Imager Detector), Components (Hardware, Software), End Users (Hospitals & Clinics, Imaging Centre, Academic and Researc...
$ 3500
Food Biotechnology Comprehensive Study by Type (Transgenic Crops, Synthetic Biology Derived Products), Food Source (Animal, Plant, Others) Players and Region - Global Market Outlook to 2030
$ 3500
Recombinant DNA Technology Comprehensive Study by Application (Gene Therapy, Clinical Diagnosis, Insulin Production, Generate Antibody Probes, Others), End users Industry (Agriculture, Food Productio...
$ 3800
Viral Vector Manufacturing Comprehensive Study by Type (Retroviruses, Lentiviruses, Adenoviruses, Adeno-associated viruses, Plant viruses, Hybrids, Others), Application (Research, Gene Therapy, Vacci...
$ 3450
ChIP-on-chip Comprehensive Study by Type (Chromatin Immunoprecipitation Sequencing Kits, Chromatin Immunoprecipitation Sequencing Array), Application (Gene Expression, Genotyping, Genome Cytogenetics...
$ 3750
High Content Screening Comprehensive Study by Type (Instruments (Cell Imaging and Analysis Systems, Flow Cytometers), Consumables (Reagents and Assay Kits, Micro plates, other), Software, Services, A...
$ 3750